Abbott Laboratories (ABT) Reported Strong One Year Amulet 360 Trial Results
Alpha Vantage · Simply Wall St · · AI-summarised by FinFlash
Abbott Laboratories (ABT) announced strong one-year VERITAS trial results for its Amulet 360 Left Atrial Appendage Occluder, showing high closure rates and low complications in non-valvular atrial fibrillation patients. This data strengthens Abbott's position in electrophysiology and structural heart devices, reinforcing its growth narrative despite broader nutritional and margin pressures.
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.